Immune checkpoint inhibitors (ICIs) immensely improved outcomes in melanoma patients. Vitiligo-like depigmentation (VLD) is a well-documented adverse event of ICIs which is well tolerated and often associated with prolonged response to treatment. The aim of this study was to assess the effect of VLD occurrence on survival in melanoma patients treated with ICIs. We conducted a retrospective analysis among unresectable stage III and stage IV melanoma patients treated with pembrolizumab or nivolumab at the University Clinical Center Niš from May 2017 to February 2024. The Chi-square or Fisher’s exact test were used to evaluate the categorical variables. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method (CI 95%; p < 0.05). Survival between the patients with or without VLD was compared using a log-rank (p < 0.05). A total of 109 patients were included, including 22 patients who developed VLD (20.2%). Median follow-up in the VLD group was 39.4 months, with 59% still alive and progression-free three years after treatment initiation. The overall response rate (ORR) was 72.7% vs. 29.9%, with 31.8% vs. 13.8% of complete responses in favor of the VLD subgroup. The occurrence of VLD was associated with significantly longer median PFS (8.148 vs. 52.862 months; p = 0.0001) and median OS (12.715 vs. NR months; p = 0.0001). Prediction of VLD occurrence is not possible, therefore, it cannot be a predictive parameter per se, however, it can be associated with prolonged response to ICI treatment in patients who develop this adverse event.
Breast cancer (BC) represents a globally significant health issue, with incidence rates varying worldwide. Radiotherapy is crucial in treating BC, however, it can cause adverse effects, including skin reactions. The aim of this research was to evaluate the impact of two different radiotherapy fractionation regimens on the occurrence and severity of acute skin toxicity in BC patients. The prospective study involved 44 patients who underwent postoperative radiotherapy. The patients were randomly divided into two groups: one group received hypofractionated regimen (40.05 Gy in 15 fractions over three weeks), while the other group received the standard fractionated regimen (50 Gy in 25 fractions over five weeks). The patients in this study were monitored weekly for acute skin toxicity throughout the duration of radiotherapy and following the completion of treatment. The patients receiving the standard fractionated regimen experienced a higher frequency and intensity of acute skin reactions, including erythema, dry desquamation, and moist desquamation. Skin reactions of grade I and II were particularly prominent in the patients receiving 50 Gy. Although the patients receiving hypofractionated radiotherapy had less severe skin reactions, mild skin changes did occur, although they were generally less prominent. The study points to the need for a careful selection of fractionation regimens in postoperative breast radiotherapy. Additionally, this study contributes to the understanding of the relationship between different radiotherapy modalities and the occurrence of acute skin toxicity, providing guidelines for optimizing treatment in BC patients.